ArticleBrain & spine2026
Pressure-controlled fibrinolytic irrigation for membranous and recurrent chronic subdural hematomas.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic subdural hematoma (cSDH) is a common neurosurgical condition with substantial recurrence after conventional evacuation. In June 2023, we introduced twist-drill craniostomy with pressure-controlled fibrinolytic irrigation therapy (TDC-FIT), developed for patients at elevated recurrence risk. Research question: This study evaluates the safety and effectiveness of TDC-FIT in reducing cSDH recurrence compared with standard approaches. Methods: We performed a retrospective comparative analysis of all consecutive cSDH procedures from January 2021 to December 2024, including twist-drill craniostomy (TDC), open craniotomy (OC), and TDC-FIT. The primary endpoint was reoperation within six months for symptomatic recurrence or inadequate evacuation-defined as residual hematoma ≥10 mm, midline shift, or persistent symptoms. Secondary endpoints included perioperative complications and outcome. Results: A total of 779 procedures were performed in 491 patients: 698 TDC (89.6%), 40 OC (5.1%), 34 TDC-FIT (4.4%), and 7 others. Overall recurrence per procedure was 30.0%. Hematoma-related membranes strongly predicted recurrence (OR 3.4; p < 0.0001). Recurrence after TDC-FIT was 8.8%, significantly lower than TDC (30.1%) and OC (25.0%) (p = 0.024). In membranous hematomas, recurrence reached 45.0% after TDC, 24.3% after OC, and 9.7% after TDC-FIT (p = 0.001). Predictive modeling matched observed recurrence for TDC but markedly overestimated recurrence for TDC-FIT and OC. Adverse events were lowest after TDC (7.4%) and TDC-FIT (8.8%) and highest after OC (20.0%). Over time, practice shifted toward minimally invasive techniques with increasing adoption of TDC-FIT. Conclusions: TDC-FIT demonstrated a favorable safety profile and substantially reduced recurrence compared with conventional techniques, supporting its integration as an effective minimally invasive alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.